Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 7, 2013, Pages 1467-1476

  Kuzmanov, Uros ^a,b   Musrap, Natasha ^a,b   Kosanam, Hari ^c   Smith, Christopher R ^c   Batruch, Ihor ^c   Dimitromanolakis, Apostolos ^b   Diamandis, Eleftherios P ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

glycobiomarker; glycopeptide; lectin; mass spectrometry; N glycosylation; ovarian cancer; sialic acid

Indexed keywords

AGAROSE; BIOLOGICAL MARKER; GLYCOPROTEIN; SIALIC ACID DERIVATIVE;

ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CANCER PATIENT; CYST FLUID; EFFUSION; ELECTROSPRAY; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; OVARY CYST; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; SAMBUCUS NIGRA; SUPERNATANT; TANDEM MASS SPECTROMETRY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AMINO ACID SEQUENCE; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; FEMALE; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; LECTINS; MIDDLE AGED; MOLECULAR SEQUENCE ANNOTATION; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PROTEOMICS; SIALYLTRANSFERASES; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84883013056     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0642     Document Type: Article

References (57)

1. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15(Suppl 3):274-81. (Pubitemid 43096594)
2. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003;21:200s-5s.
3. Cummings RD. The repertoire of glycan determinants in the human glycome. Mol Biosyst 2009;5:1087-104.
4. Drake PM, Cho W, Li B, Prakobphol A, Johansen E, Anderson NL, et al. Sweetening the pot: Adding glycosylation to the biomarker discovery equation. Clin Chem 2010;56:223-36.
5. Hedlund M, Ng E, Varki A, Varki NM. Alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 2008;68:388-94. (Pubitemid 351380065)
6. Wang PH, Lee WL, Juang CM, Yang YH, Lo WH, Lai CR, et al. Altered mRNA expressions of sialyltransferases in ovarian cancers. Gynecol Oncol 2005;99:631-9.
7. Lukk M, Kapushesky M, Nikkila J, Parkinson H, Goncalves A, Huber W, et al. A global map of human gene expression. Nat Biotechnol 2010;28:322-4.
8. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Art. 3.
9. Drake PM, Schilling B, Niles RK, Braten M, Johansen E, Liu H, et al. A lectin affinity workflow targeting glycosite-specific, cancer-related carbohydrate structures in trypsin-digested human plasma. Anal Biochem 2011;408:71-85.
10. Wang PH, Lo WL, Hsu CC, Lin TW, Lee WL, Wu CY, et al. Different enzyme activities of sialyltransferases in gynecological cancer cell lines. Eur J Gynaecol Oncol 2002;23:221-6. (Pubitemid 34625329)
11. Saldova R, Wormald MR, Dwek RA, Rudd PM. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers 2008;25: 219-32.
12. Christie DR, Shaikh FM, Lucas JAt, Lucas JA 3rd, Bellis SL. ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res 2008;1:3.
13. Swindall AF, Bellis SL. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem 2011;286:22982-90.
14. Liu Z, Swindall AF, Kesterson RA, Schoeb TR, Bullard DC, Bellis SL. ST6Gal-I regulates macrophage apoptosis via alpha2-6 sialylation of the TNFR1 death receptor. J Biol Chem 2011;286:39654-62.
15. Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, Diamandis EP. Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol Cell Proteomics 2009;8:791-8.
16. Kuzmanov U, Smith CR, Batruch I, Soosaipillai A, Diamandis A, Diamandis EP. Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. Proteomics 2012;12:799-809.
17. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics 2009;8:661-9.
18. Sarria A, Moreno LA, Mur M, Lazaro A, Lasierra MP, Roda L, et al. Relationship between immunoinflammatory proteins containing sialic acid and low-density lipoprotein serum concentrations. Clin Chim Acta 1996;252:21-31. (Pubitemid 26227776)
19. Shield-Artin KL, Bailey MJ, Oliva K, Liovic AK, Barker G, Dellios NL, et al. Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics. Proteomics Clin Appl 2012;6:170-81.
20. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, et al. Afamin and apolipoprotein A-IV: Novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1127-33.
21. Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007;13:7370-9.
22. Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS. Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci 2010;8:58.
23. Meri S, Lehto T, Sutton CW, Tyynela J, Baumann M. Structural composition and functional characterization of soluble CD59: Heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochem J 1996;316:923-35.
24. Yang GF, Li XM, Xie D. Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 2009;19:1342-6.
25. Yokoyama M, Matsue H, Muramoto K, Sasaki M, Ono K, Endo M. Isolation and characterization of sulfated glycoprotein from human pancreatic juice. Biochim Biophys Acta 1988;967:34-42.
26. Hough C, Cho K, Zonderman A, Schwartz D, Morin P. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-76. (Pubitemid 32720943)
27. Losch A, Schindl M, Kohlberger P, Lahodny J, Breitenecker G, Horvat R, et al. Cathepsin D in ovarian cancer: Prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol 2004;92:545-52. (Pubitemid 38183143)
28. Okude M, Yamanaka A, Morimoto Y, Akihama S. Sialic acid in fibrinogen: Effects of sialic acid on fibrinogen-fibrin conversion by thrombin and properties of asialofibrin clot. Biol Pharm Bull 1993;16:448-52. (Pubitemid 23208660)
29. Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: A multi-centre trial. Br J Cancer 2010;102:952-6.
30. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007;17:1344-56. (Pubitemid 350131311)
31. Ferdeghini M, Gadducci A, Prontera C, Annicchiarico C, Gagetti O, Bianchi M, et al. Preoperative serum intercellular adhesion molecule-1 (ICAM-1) and E-selectin (endothelial cell leukocyte adhesion molecule, ELAM-1) in patients with epithelial ovarian cancer. Anticancer Res 1995;15:2255-60. (Pubitemid 26031308)
32. Amankwah EK, Wang Q, Schildkraut JM, Tsai YY, Ramus SJ, Fridley BL, et al. Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: A report from the Ovarian Cancer Association Consortium. PLoS One 2011;6:e19642.
33. Karlsson NG, McGuckin MA. O-linked glycome and proteome of high molecular mass proteins in human ovarian cancer ascites: Identification of sulfation, disialic acid and O-linked fucose. Glycobiology 2012;22:918-29.
34. Jankovic MM, Milutinovic BS. Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark 2008;4:35-42. (Pubitemid 351343910)
35. Mitic N, Milutinovic B, Jankovic M. Assessment of sialic acid diversity in cancer-and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs). Dis Markers 2012;32:187-94.
36. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 2009;18:47-56.
37. Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, et al. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer 2008;123:2130-7.
38. Shori DK, Genter T, Hansen J, Koch C, Wyatt H, Kariyawasam HH, et al. Altered sialyl-and fucosyl-linkage on mucins in cystic fibrosis patients promotes formation of the sialyl-Lewis X determinant on salivary MUC-5B and MUC-7. Pflugers Arch 2001;443(Suppl 1):S55-61. (Pubitemid 33086953)
39. Budai L, Ozohanics O, Ludanyi K, Drahos L, Kremmer T, Krenyacz J, et al. Investigation of genetic variants of alpha-1 acid glycoprotein by ultra-performance liquid chromatography-mass spectrometry. Anal Bioanal Chem 2009;393:991-8.
40. Imre T, Kremmer T, Heberger K, Molnar-Szollosi E, Ludanyi K, Pocsfalvi G, et al. Mass spectrometric and linear discriminant analysis of N-glycans of human serum alpha-1-acid glycoprotein in cancer patients and healthy individuals. J Proteomics 2008;71:186-97. (Pubitemid 351927284)
41. Sarrats A, Saldova R, Pla E, Fort E, Harvey DJ, Struwe WB, et al. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl 2010;4:432-48.
42. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, et al. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990;265:6453-60.
43. Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785-93.
44. Tetu B, Popa I, Bairati I, LaEsperance S, Bachvarova M, Plante M, et al. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol 2008;21:1002-10.
45. Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, Cibula D, et al. Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics. Oncol Rep 2011;27:318-24.
46. LaEsperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: Molecular signatures of chemoresistant tumors. Int J Oncol 2006;29:5-24.
47. Normandin K, Peant B, Le Page C, de Ladurantaye M, Ouellet V, Tonin PN, et al. Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clin Exp Metastasis 2010;27:55-69.
48. Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap KL, et al. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One 2010;5:e11198.
49. Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih Ie M, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med 2010;15:535-44.
50. Gornik O, Lauc G. Enzyme linked lectin assay (ELLA) for direct analysis of transferrin sialylation in serum samples. Clin Biochem 2007;40:718-23. (Pubitemid 46829062)
51. Hogdall C, Fung ET, Christensen IJ, Nedergaard L, Engelholm SA, Petri AL, et al. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol 2011;123:308-13.
52. Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2007;106:221-32. (Pubitemid 46908745)
53. Ahn HJ, Kim YS, Lee CH, Cho EW, Yoo HS, Kim SH, et al. Generation of antibodies recognizing an aberrant glycoform of human tissue inhibitor of metalloproteinase-1 (TIMP-1) using decoy immunization and phage display. J Biotechnol 2010;151:225-30.
54. Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C, Dorigo O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) 2010;67:535-44.
55. Mohamed E, Abdul-Rahman PS, Doustjalali SR, Chen Y, Lim BK, Omar SZ, et al. Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. Electrophoresis 2008;29:2645-50. (Pubitemid 351911892)
56. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter J, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700. (Pubitemid 36793054)
57. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol 2011;125:65-9.